Central toxic keratopathy presence associated with postoperative medication changes

Article

A recent study published in Cornea has announced the presence of central toxic keratopathy is linked to postoperative medication changes and bandage lens practice.

A recent study published in Cornea has announced the presence of central toxic keratopathy is linked to postoperative medication changes and bandage lens practice.

The investigation led by Dr Waldir Neira, Department of Ophthalmology, Helsinki University Central Hospital, Finland, consisted of 5 eyes of 5 patients with central toxic keratopathy after photorefractive keratectomy (PRK). A VISX S4 excimer laser was used to perform laser ablations on all 5 patients who experienced a corneal stromal thinning linked to a central opacification, hyperopic shift and central striae during the first postoperative week.

Uncorrected visual acuity, best spectacle-corrected visual acuity (BCVA), manifest retraction, biomicroscopy and ultrasound pachymetry were examined at 1 month, 2 months, 6 months and 12 months at follow-up. Additionally, confocal microscopy was performed in 3 eyes at final follow-up.

The postoperative results of the first month's follow-up demonstrated that corneal thickness measured by ultrasound pachymetry showed a stromal thinning of 48 ± 39 μm, compared to the expected results. At the final follow-up, corneal thickness increased by 44 ± 22 μm, compared to the thickness recorded at the first postoperative month.

BCVA, central opacification, corneal thickness and uncorrected visual acuity improved during the initial postoperative month and were maintained after 6 months.

The study also suggests that stromal dehydration may be caused by an unknown pharmalogical response. Central toxic keratopathy can be associated with simultaneous change of both postoperative medications and postoperative bandage lens practice.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.